Clareo Health | A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CSL Behring
Age
6–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females aged 6 years or older.
A confirmed diagnosis of HAE type I or II.
HAE attacks over a consecutive 2-month period that required acute treatment, medical attention, or caused significant functional impairment.
For subjects who have used oral therapy for prophylaxis against HAE attacks within 3 months of first study visit: use of a stable regimen within 3 months of the first study visit.
You may not be if
Incurable malignancies.
Any clinical condition that will interfere with the evaluation of C1-INH therapy.
Clinically significant history of poor response to C1-esterase therapy for the management of HAE.
Suspected or confirmed diagnosis of acquired HAE or HAE with normal C1-INH.
Inability to have HAE managed pharmacologically with on-demand treatment.
